NSCLC患者多途径标本检测EGFR基因突变研究进展  

Research Progress of EGFR Gene Mutation in NSCLC Patients with Multiple Pathway Specimens

作　　者：吴晓岚[1] 杨维群[1] 

机构地区：[1]泉州医学高等专科学校基础医学部,泉州362000

出　　处：《四川解剖学杂志》2016年第4期38-42,共5页Sichuan Journal of Anatomy

基　　金：泉州市科技计划重点项目(2014Z34)

摘　　要：表皮生长因子受体(EGFR)属受体酪氨酸激酶家族,调控细胞的增殖、分化、血管生成及凋亡,其信号通路与恶性肿瘤的增殖、侵袭及转移关系紧密。非小细胞肺癌(NSCLC)中发现EGFR酪氨酸激酶区常发生各种突变,这些突变和酪氨酸激酶抑制剂(TKIs)的疗效密切相关。因此,EGFR基因突变的检测是靶向药物EGFR-TKIs治疗有效的一个重要因素及预测指标。本文就NSCLC患者EGFR基因突变不同标本来源,如原发灶肿瘤组织、转移淋巴结组织、外周血、胸腔积液标本检测,做一介绍。Epidermal growth factor receptor（EGFR）is one member of tyrosine kinase receptors,which regulating the growth,differentiation,angiogenesis and apoptosis of human cell.The receptor＇s signal pathway takes part in the growth,invasion,and metastasis of malignant tumors.The mutations in EGFR tyrosine area,that related to the therapeutic effect of tyrosine kinase inhibitors（TKIs）,are often found in patients with non-small cell lung cancer（NSCLC）.Accordingly,the effect of EGFR-TKIs can be expected by the detection of mutation in EGFR gene.However,the samples for detecting mutation of EGFR are of many kinds,such as primary focal cancer,metastasis lymph node tissue,peripheral blood and pleural effusion.In this review,the current state-of-the-art advantage and disadvantage of those samples for the detection is described.

关 键 词：NSCLC EGFR基因突变 淋巴结 外周血 胸腔积液 

分 类 号：R734.2[医药卫生—肿瘤]